A Study Looking at Novel Scheduling of Cabazitaxel for Patients With Metastatic Prostate Cancer
Status:
Completed
Trial end date:
2015-10-01
Target enrollment:
Participant gender:
Summary
Cabazitaxel has shown significant efficacy as second line chemotherapy after Docetaxel in men
with metastatic castration resistant prostate cancer. This was demonstrated in the Tropic
Study where Cabazitaxel showed survival superiority compared to mitoxantrone. Almost one in 4
patients treated with Cabazitaxel in this study required dose reductions or dose delays or
stopped treatment due to toxicity. ConCab examines another scheduling for cabazitaxel to see
if we can improve tolerability so that patients will receive a higher percentage of the
treatment as planned.